Selective Serotonin Reuptake Inhibitors / Depressive Disorder · Journal article

Antipsychotic medication and the prevention of psychiatric emergencies in difficult-to-treat adolescent depression.

Journal of Affective Disorders · August 14, 2026

Strong Evidence Why this matters to you Expert discussion

Well-designed and adequately powered for the question it asks.

AI Summary

This propensity-score-weighted cohort study of 32,237 adolescents with depression found that initiation of atypical antipsychotics was associated with significantly higher risk of psychiatric emergencies compared to secondary antidepressants over one year of follow-up. The findings do not support a protective effect of antipsychotics in difficult-to-treat adolescent depression and suggest potential harm relative to antidepressant escalation.

What was studied

Propensity-score-weighted retrospective cohort study using target trial emulation. Adolescents aged 10–19 years with depression who had filled SSRI prescriptions within 1 year before initiating a secondary medication (antipsychotic or antidepressant), with no FDA-approved pediatric antipsychotic indications.. Intervention: Atypical antipsychotic medication initiation. Compared with: Secondary antidepressant medication initiation. n = 32,237. United States (Optum database).

Key findings

Antipsychotic initiation associated with hazard ratio 1.59 (95% CI 1.46–1.72) for psychiatric emergencies versus secondary antidepressants Weighted cumulative incidence of psychiatric emergencies: 38.7% (95% CI 34.8%–42.7%) with antipsychotics versus 24.5% (95% CI 23.7%–25.3%) with antidepressants at 1 year Comparable elevated risk observed for emergencies involving suicidality

Safety

Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.

Who this may help

Clinicians should be cautious about initiating atypical antipsychotics in adolescents with difficult-to-treat depression, as this analysis suggests increased risk of psychiatric emergencies compared to secondary antidepressant strategies. The findings argue for preferential consideration of antidepressant escalation or augmentation in this population.

Plain-language summary

Large observational cohort study with propensity-score weighting comparing antipsychotics to antidepressants for a hard clinical outcome (psychiatric emergency visits/admissions) in adolescents with difficult-to-treat depression, showing increased risk with antipsychotics and consistent results across sensitivity analyses.

Study design

As stated by the source record.

MethodsDe-identified electronic health record data from Optum Clinformatics® Data Mart (2009–2021) were used to identify adolescents with depression who had received SSRI treatment and then initiated either a new atypical antipsychotic or secondary antidepressant. Propensity-score weighting was applied to reduce confounding bias between treatment groups. The primary outcome was psychiatric emergency visits or inpatient mental health encounters within 1 year of medication initiation. Hazard ratios and cumulative incidence proportions with 95% confidence intervals were calculated; sensitivity analyses…

DesignPropensity-score-weighted retrospective cohort study using target trial emulation

PopulationAdolescents aged 10–19 years with depression who had filled SSRI prescriptions within 1 year before initiating a secondary medication (antipsychotic or antidepressant), with no FDA-approved pediatric antipsychotic indications.

Sample size32,237

InterventionAtypical antipsychotic medication initiation

ComparatorSecondary antidepressant medication initiation

SettingUnited States (Optum database)

Reported figures

Quoted from the source exactly as published.

Hazard ratio (antipsychotic vs. antidepressant)1.59

95% CI for hazard ratio1.46, 1.72

Cumulative incidence, antipsychotics38.7%

95% CI cumulative incidence, antipsychotics34.8%, 42.7%

Cumulative incidence, antidepressants24.5%

95% CI cumulative incidence, antidepressants23.7%, 25.3%

Sample size, antipsychotic users3710

Sample size, antidepressant users28527

Clinical bottom line

Caveats

Observational design limits causal inference; residual confounding by indication and unmeasured confounders cannot be excluded.
Propensity-score weighting may not fully adjust for differences in clinical complexity between antipsychotic-versus-antidepressant-treated groups.
No direct information provided on medication adherence, dosing, or appropriateness of prescribing decisions.
Generalizability limited to US insured population represented in Optum database; results may not apply to other healthcare systems or demographic groups.

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Study design

strong

Target trial emulation framework with propensity-score weighting to reduce confounding bias.

Directness

strong

Directly compares antipsychotics versus antidepressants for psychiatric emergencies in adolescents with depression.

Consistency

strong

Comparable results observed for suicidality-involving emergencies and in series of sensitivity analyses.

Risk of bias

moderate

Observational design; propensity weighting addresses selection bias but residual confounding possible; unmeasured confounders cannot be excluded.

Sample adequacy

strong

Large sample: 3710 antipsychotic and 28,527 antidepressant users with adequate events for hazard ratio estimation.

Source abstract

Objectives. It is unclear how antipsychotic medications affect acute healthcare use among adolescents with depression. We compared risk of psychiatric emergencies between adolescents with difficult-to-treat depression initiating new antipsychotic versus antidepressant medications.Methods. This cohort study employed a target trial emulation framework using Optum's de-identified Clinformatics® Data Mart Database between 2009 and 2021. We compared risk of emergency visits or inpatient encounters with mental health diagnoses (i.e. psychiatric emergencies) following new atypical antipsychotic versus secondary antidepressant prescription fills among adolescents (10-19 years old) with depression. All adolescents had filled SSRI prescriptions within one year prior to initiating a secondary medication and had no FDA-approved indications for pediatric antipsychotic use.Results. Among youth with depression and SSRI receipt, there were 3710 incident antipsychotic users (63.7% female) and 28,527 secondary antidepressant users (71.7% female). Within 1 year of initiation, antipsychotic medications were associated with a higher risk of psychiatric emergencies (propensity-score weighted HR = 1.59; 95% CI = 1.46, 1.72) compared with secondary antidepressant medications. The weighted cumulative incidence of psychiatric emergencies was 38.7% (95% CI = 34.8%, 42.7%) for antipsychotic and 24.5% (95% CI = 23.7%, 25.3%) for secondary antidepressant users. Comparable results were observed for emergencies involving suicidality and in a series of sensitivity analyses.Conclusions. Our findings do not provide support for a protective effect of atypical antipsychotic medications compared with secondary antidepressant medications for the prevention of psychiatric emergencies in youth with difficult-to-treat depression.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.

Patrick D QuinnTanya E FroehlichRichard F MerazMichael D MorseLinnea Sepe-ForrestSelective Serotonin Reuptake InhibitorsDepressive DisorderZheng Chang